Aggressive Prolactinoma: Next-Line Management After Temozolomide Failure

This protocol addresses invasive prolactin-secreting pituitary adenoma with documented persistent growth despite exhausting all prior treatment modalities — including chemotherapy — and defines the structured evidence-based approach taken once earlier treatment goals are not met.

Clinical Situation

The patient presents with an aggressive prolactinoma: an invasive pituitary adenoma showing unusually rapid growth, or clinically relevant growth despite maximal tolerated dopamine agonist doses, with documented persistent adenoma growth despite all treatment modalities.

Previous Treatment — Failure Condition

The prior treatment line, Temozolomide (an alkylating chemotherapeutic agent), did not achieve its primary goal of at least partial remission with mass shrinkage, evaluated at 3 months. Non-achievement of this target triggers escalation to the current protocol.

Next-Line Approach — Partial Overview

Following Temozolomide failure, this protocol involves an immune checkpoint inhibitor-based approach aimed at achieving mass shrinkage. The complete agent selection criteria, sequencing, and clinical decision framework are available in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1038/s41574-023-00886-5

Aggressive prolactinomas are defined as invasive adenomas with an unusually rapid growth rate or adenomas with clinically relevant growth despite maximal tolerated dopamine agonist doses (strong).
In patients with aggressive prolactinomas and documented persistent adenoma growth despite exhausting all treatment modalities, the chemotherapeutic agent temozolomide is recommended (strong).
The use of immune-checkpoint inhibitors could be a viable option for aggressive prolactinomas after temozolomide failure (weak).
In prolactin-secreting carcinomas, immunotherapy with the checkpoint inhibitors ipilimumab and nivolumab induced responses, including mass shrinkage, suggesting that these drugs could be an option if temozolomide fails in aggressive prolactinoma.

View source ↗